Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III)

TJ. Sferra, T. Merta, M. Neely, C. Murta de Oliveira, A. Lassaletta, C. Fortuny Guasch, MB. Dorr, G. Winchell, FH. Su, S. Perko, D. Fernsler, H. Waskin, SR. Holden

. 2023 ; 12 (6) : 334-341. [pub] 2023Jun30

Language English Country England, Great Britain

Document type Randomized Controlled Trial, Multicenter Study, Journal Article

Persistent link   https://www.medvik.cz/link/bmc23017040

Grant support
Merck Sharp & Dohme

BACKGROUND: Therapies to prevent recurrence of Clostridioides difficile infection (CDI) in pediatric patients are needed. Bezlotoxumab is a fully human monoclonal antibody approved for prevention of recurrent CDI in adults. We assessed the pharmacokinetics, safety, tolerability, and efficacy of bezlotoxumab in pediatric patients. METHODS: MODIFY III was a multicenter, double-blind, placebo-controlled study of bezlotoxumab in children (1 to <18 years) receiving antibacterial treatment for CDI. Participants were randomized 3:1 to receive a single infusion of bezlotoxumab (10 mg/kg) or placebo and were stratified by age at randomization (cohort 1: 12 to <18 years, cohort 2: 1 to <12 years). The primary objective was to characterize bezlotoxumab pharmacokinetics to support dose selection for pediatric patients; the primary endpoint was the area under the bezlotoxumab serum concentration-time curve (AUC0-inf). Safety, tolerability, and efficacy were monitored for 12 weeks post-infusion. RESULTS: A total of 148 participants were randomized and 143 were treated: 107 with bezlotoxumab and 36 with placebo (cohort 1 n = 60, cohort 2 n = 83; median age 9.0 years); 52.4% of participants were male and 80.4% were white. Geometric mean ratios (90% CI) for bezlotoxumab AUC0-inf were 1.06 (0.95, 1.18) and 0.82 (0.75, 0.89) h * μg/mL for cohorts 1 and 2, respectively. Bezlotoxumab 10 mg/kg was generally well-tolerated with an adverse event profile similar to placebo, including no treatment discontinuations due to adverse events. CDI recurrence was low and comparable for bezlotoxumab (11.2%) and placebo (14.7%). CONCLUSIONS: The results of this study support the bezlotoxumab dose of 10 mg/kg for pediatric patients. TRIAL REGISTRATION: NCT03182907 at ClinicalTrials.gov.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23017040
003      
CZ-PrNML
005      
20231026105339.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/jpids/piad031 $2 doi
035    __
$a (PubMed)37389891
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Sferra, Thomas J $u Department of Pediatrics, UH Rainbow Babies & Children's Hospital and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
245    10
$a Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III) / $c TJ. Sferra, T. Merta, M. Neely, C. Murta de Oliveira, A. Lassaletta, C. Fortuny Guasch, MB. Dorr, G. Winchell, FH. Su, S. Perko, D. Fernsler, H. Waskin, SR. Holden
520    9_
$a BACKGROUND: Therapies to prevent recurrence of Clostridioides difficile infection (CDI) in pediatric patients are needed. Bezlotoxumab is a fully human monoclonal antibody approved for prevention of recurrent CDI in adults. We assessed the pharmacokinetics, safety, tolerability, and efficacy of bezlotoxumab in pediatric patients. METHODS: MODIFY III was a multicenter, double-blind, placebo-controlled study of bezlotoxumab in children (1 to <18 years) receiving antibacterial treatment for CDI. Participants were randomized 3:1 to receive a single infusion of bezlotoxumab (10 mg/kg) or placebo and were stratified by age at randomization (cohort 1: 12 to <18 years, cohort 2: 1 to <12 years). The primary objective was to characterize bezlotoxumab pharmacokinetics to support dose selection for pediatric patients; the primary endpoint was the area under the bezlotoxumab serum concentration-time curve (AUC0-inf). Safety, tolerability, and efficacy were monitored for 12 weeks post-infusion. RESULTS: A total of 148 participants were randomized and 143 were treated: 107 with bezlotoxumab and 36 with placebo (cohort 1 n = 60, cohort 2 n = 83; median age 9.0 years); 52.4% of participants were male and 80.4% were white. Geometric mean ratios (90% CI) for bezlotoxumab AUC0-inf were 1.06 (0.95, 1.18) and 0.82 (0.75, 0.89) h * μg/mL for cohorts 1 and 2, respectively. Bezlotoxumab 10 mg/kg was generally well-tolerated with an adverse event profile similar to placebo, including no treatment discontinuations due to adverse events. CDI recurrence was low and comparable for bezlotoxumab (11.2%) and placebo (14.7%). CONCLUSIONS: The results of this study support the bezlotoxumab dose of 10 mg/kg for pediatric patients. TRIAL REGISTRATION: NCT03182907 at ClinicalTrials.gov.
650    _2
$a dospělí $7 D000328
650    _2
$a lidé $7 D006801
650    _2
$a dítě $7 D002648
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dvojitá slepá metoda $7 D004311
650    12
$a antibakteriální látky $x terapeutické užití $7 D000900
650    _2
$a monoklonální protilátky $x terapeutické užití $7 D000911
650    12
$a klostridiové infekce $x farmakoterapie $7 D003015
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
700    1_
$a Merta, Tomas $u Department of Pediatric Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Neely, Michael $u Division of Infectious Diseases, Children's Hospital Los Angeles, Los Angeles, California, USA $1 https://orcid.org/0000000216758276
700    1_
$a Murta de Oliveira, Claudia $u Santa Casa de Misericórdia, Belo Horizonte, Brazil
700    1_
$a Lassaletta, Alvaro $u Pediatric Hematology-Oncology Department, Hospital Niño Jesus, Madrid, Spain
700    1_
$a Fortuny Guasch, Claudia
700    1_
$a Dorr, Mary Beth $u PPDM QP2, Merck & Co., Inc., Rahway, New Jersey, USA
700    1_
$a Winchell, Gregory $u Biostatistics, Merck & Co., Inc., Rahway, New Jersey, USA
700    1_
$a Su, Feng-Hsiu $u Clinical Operations, Merck & Co., Inc., Rahway, New Jersey, USA
700    1_
$a Perko, Sarah $u Clinical Research, MSD UK, London, UK
700    1_
$a Fernsler, Doreen $u Clinical Research, MSD UK, London, UK
700    1_
$a Waskin, Hetty $u PPDM QP2, Merck & Co., Inc., Rahway, New Jersey, USA
700    1_
$a Holden, Stephen R $u Clinical Research, MSD UK, London, UK
773    0_
$w MED00214008 $t Journal of the Pediatric Infectious Diseases Society $x 2048-7207 $g Roč. 12, č. 6 (2023), s. 334-341
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37389891 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105334 $b ABA008
999    __
$a ok $b bmc $g 2000522 $s 1203402
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 12 $c 6 $d 334-341 $e 2023Jun30 $i 2048-7207 $m Journal of the Pediatric Infectious Diseases Society $n J Pediatric Infect Dis Soc $x MED00214008
GRA    __
$p Merck Sharp & Dohme
LZP    __
$a Pubmed-20231013

Find record

Citation metrics

Logged in users only

Archiving options